Irene Beune
University Medical Center Groningen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Irene Beune.
Ultrasound in Obstetrics & Gynecology | 2016
Sanne J. Gordijn; Irene Beune; B. Thilaganathan; A. T. Papageorghiou; A. A. Baschat; P. N. Baker; Robert M. Silver; Klaske Wynia; Wessel Ganzevoort
To determine, by expert consensus, a definition for early and late fetal growth restriction (FGR) through a Delphi procedure.
Ultrasound in Obstetrics & Gynecology | 2016
Sanne J. Gordijn; Irene Beune; B. Thilaganathan; A.T. Papageorghiou; A. A. Baschat; P. N. Baker; Robert M. Silver; Klaske Wynia; Wessel Ganzevoort
To determine, by expert consensus, a definition for early and late fetal growth restriction (FGR) through a Delphi procedure.
Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health | 2014
Miriam F. Van Oostwaard; Josje Langenveld; Ewoud Schuit; Kiki Wigny; Hilde Van Susante; Irene Beune; Roos Ramaekers; Dimitri Papatsonis; Ben Willem J. Mol; Wessel Ganzevoort
OBJECTIVES To assess the recurrence risk of term hypertensive disease of pregnancy and to determine which potential risk factors are predictive of recurrence. STUDY DESIGN We performed a retrospective cohort study in two secondary and one tertiary care hospitals in the Netherlands. We identified women with a hypertensive disorder in the index pregnancy and delivery after 37weeks of gestation between January 2000 and December 2002. Data were extracted from medical files and women were approached for additional information on subsequent pregnancies. Adverse outcome was defined as recurrence of a hypertensive disorder in the next subsequent pregnancy. MAIN OUTCOME MEASURES The absolute risk of recurrence and a prediction model containing demographic and clinical factors predictive of recurrence. RESULTS We identified 638 women for potential inclusion, of whom 503 could be contacted. Of these women, 312 (62%) had a subsequent pregnancy. Hypertensive disorders recurred in 120 (38%, 95% CI 33-44) women, of whom 15 (5%, 95% CI 3-7) delivered preterm. Women undergoing recurrence were more at risk to develop chronic hypertension after pregnancy (35% versus 16%, OR 2.8, 95% CI 1.5-5.3). Body mass index, non-White European origin, chronic hypertension, maximum diastolic blood pressure, no use of anticonvulsive medication and interpregnancy interval were predictors for recurrence. CONCLUSIONS Women with hypertensive disorders and term delivery have a substantial chance of recurrence, but a small risk of preterm delivery. A number of predictors for recurrence could be identified and women with a recurrence more often developed chronic hypertension.
Ultrasound in Obstetrics & Gynecology | 2018
Asma Khalil; Irene Beune; Kurt Hecher; Klaske Wynia; Wessel Ganzevoort; Keith Reed; Liesbeth Lewi; Dick Oepkes; E. Gratacós; Basky Thilaganathan; Sanne J. Gordijn
Twin pregnancy complicated by selective fetal growth restriction (sFGR) is associated with increased perinatal mortality and morbidity. Inconsistencies in the diagnostic criteria for sFGR employed in existing studies hinder the ability to compare or combine their findings. It is therefore challenging to establish robust evidence‐based management or monitoring pathways for these pregnancies. The main aim of this study was to determine, by expert consensus using a Delphi procedure, the key diagnostic features of and the essential reporting parameters in sFGR.
Best Practice & Research in Clinical Obstetrics & Gynaecology | 2018
Sanne J. Gordijn; Irene Beune; Wessel Ganzevoort
Fetal growth restriction is a pathologic condition in which the fetus fails to reach its biologically based growth potential. There is inconsistency in terminology, definition, monitoring, and management, both in clinical practice and in the existing literature. This hampers interpretation and comparison of cohorts and studies. Standardization is essential. With the lack of a golden standard, or the opportunity to come to empirical evidence, consensus procedures can help to establish standardization. Consensus procedures provide no new information but formulate an agreement (as second best in the absence of robust evidence) for clinical and/or research practice on the basis of existing data. Consensus agreements need to be updated when new evidence becomes available and can change over time. In this chapter, we address the different issues that lack uniformity in FGR studies and management. Furthermore, we discuss several consensus methods and recent consensus procedures regarding fetal growth restriction.
Ultrasound in Obstetrics & Gynecology | 2016
Sanne J. Gordijn; Irene Beune; B. Thilaganathan; A. T. Papageorghiou; A. A. Baschat; P. N. Baker; Robert M. Silver; Klaske Wynia; Wessel Ganzevoort
To determine, by expert consensus, a definition for early and late fetal growth restriction (FGR) through a Delphi procedure.
Ultrasound in Obstetrics & Gynecology | 2018
Asma Khalil; Sanne J. Gordijn; Irene Beune; Klaske Wynia; Wessel Ganzevoort; Francesc Figueras; John Kingdom; Neil Marlow; A. T. Papageorghiou; Nj Sebire; Jennifer Zeitlin; A. A. Baschat
To determine, by expert consensus using a Delphi procedure, a minimum reporting set of study variables for fetal growth restriction (FGR) research studies.
Ultrasound in Obstetrics & Gynecology | 2018
Irene Beune; A. Pels; Sanne J. Gordijn; Wessel Ganzevoort
Fetal growth restriction (FGR) is a major health problem because it has a significant contribution to perinatal mortality and morbidity.(1, 2) Long-term health outcomes, such as neurological- and cognitive development, cardiovascular and endocrine diseases, are negatively influenced by an adverse intrauterine environment.(3) This article is protected by copyright. All rights reserved.
Trials | 2018
Patricia Healy; Sanne J. Gordijn; Wessel Ganzevoort; Irene Beune; A. A. Baschat; Asma Khalil; Louise C. Kenny; Frank H. Bloomfield; Mandy Daly; A T Papageorghiou; Declan Devane
BackgroundFoetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems, including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare because of differences in the selection and definition of outcomes. To enable future trials to measure similar, meaningful outcomes, we are developing two core outcome sets (COS) – one for prevention and the other for treatment of FGR.MethodsWe will review the literature to identify previously reported outcomes. An international panel of relevant stakeholders who have experience of FGR (parent or carer of a baby that was growth restricted, health professional involved in the care of mothers and babies affected by FGR, a person with expertise in FGR research) will rate the importance of each of those outcomes in a series of three sequential online rounds of a Delphi study. Participants will be able to add items to the proposed list in round 1. A final face-to-face consensus meeting will be held with representatives of each stakeholder group at which a final list of outcomes for inclusion in the COS will be agreed.DiscussionThe development of COSs in FGR will ensure the collection and reporting of a minimum dataset agreed by stakeholder consensus and will reduce inconsistencies in the reporting of outcomes across relevant trials. Such standardisation in the reporting of outcomes will improve synthesis of evidence and generalisability of knowledge in the future by reducing heterogeneity in outcomes between trials and thus improve the results of systematic reviews and meta-analyses. Ultimately, we hope that the COSs will lead to an improvement in the quality of evidence-based clinical practice, enhance patient care, and improve the quality and consistency of research.Trial registrationNot applicable. This study is registered in the Core Outcome Measures for Effectiveness (COMET) database.
The Journal of Pediatrics | 2018
Irene Beune; Frank H. Bloomfield; Wessel Ganzevoort; Nicholas D. Embleton; Paul J. Rozance; Aleid G. van Wassenaer-Leemhuis; Klaske Wynia; Sanne J. Gordijn
Objective To develop a consensus definition of growth restriction in the newborn that can be used clinically to identify newborn infants at risk and in research to harmonize reporting and definition in the current absence of a gold standard. Study design An international panel of pediatric leaders in the field of neonatal growth were invited to participate in an electronic Delphi procedure using standardized methods and predefined consensus rules. Responses were fed back at group‐level and the list of participants was provided. Nonresponders were excluded from subsequent rounds. In the first round, variables were scored on a 5‐point Likert scale; in subsequent rounds, inclusion of variables and cut‐offs were determined with a 70% level of agreement. In the final round participants selected the ultimate algorithm. Results In total, 57 experts participated in the first round; 79% completed the procedure. Consensus was reached on the following definition: birth weight less than the third percentile, or 3 out of the following: birth weight <10th percentile; head circumference <10th percentile; length <10th percentile; prenatal diagnosis of fetal growth restriction; and maternal pregnancy information. Conclusions Consensus was reached on a definition for growth restriction in the newborn. This definition recognizes that infants with birth weights <10th percentile may not be growth restricted and that infants with birth weights >10th percentile can be growth restricted. This definition can be adopted in clinical practice and in clinical trials to better focus on newborns at risk, and is complementary to the previously determined definition of fetal growth restriction.